Abstract
Alzheimer's disease (AD) is the most prevalent form of dementia, and it is
considered a dynamic cognitive decline. Neurofibrillary tangles and nerve cell injury
are important neuropharmacological symptoms for one AD brain. TMP21 is an
important molecule in cellular protein trafficking. TMP21, a protein involved in the
production of neurotic plaques, appears to be dysregulated in AD. As a result, we want
to look into TMP21 dysregulation in Alzheimer's disease, as well as the involvement of
TMP21 in neurotic plaque development and the underlying mechanisms. TMP21's
significance in the creation of neurofibrillary tangles, synaptic disbalance, and nerve
cell death is also explored. It will shed light on the therapeutic potential of regulating
TMP21 as a treatment for AD.
Keywords: Amyloid beta protein, Alzheimer’s disease, Glycogen synthase kinase-3, Tau phosphorylation, TMP21.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Drug Delivery
Current Bioactive Compounds
Current Drug Safety
Reviews on Recent Clinical Trials
Drug Delivery Letters
Recent Advances in Drug Delivery and Formulation
Recent Advances in Anti-Infective Drug Discovery
Drug Metabolism and Bioanalysis Letters
Applied Drug Research, Clinical Trials and Regulatory Affairs
Related Books
Biotechnology and Drug Development for Targeting Human Diseases
4th International Conference on Drug Discovery and Therapy - 2012
Applied Computer-Aided Drug Design: Models and Methods
Computational Toxicology for Drug Safety and a Sustainable Environment
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development
Anti-Angiogenesis Drug Discovery and Development